# DESCRIPTION

## FIELD OF THE INVENTION

- relate to treating chronic kidney disease

## BACKGROUND OF THE INVENTION

- define chronic kidney disease
- discuss prevalence and poor therapeutic outcomes
- motivate need for new treatment approaches

## SUMMARY OF THE INVENTION

- introduce therapeutic composition of bioactive renal cells
- describe method of treating CKD with composition
- outline various embodiments of administration
- specify patient populations and diagnosis
- summarize improved kidney function outcomes

## DETAILED DESCRIPTION OF THE INVENTION

- disclaim limitations of embodiments

### Definitions

- define technical terms
- specify meaning of "comprise" and similar words
- define "cell population"
- explain isolation and culturing of cell populations
- define "bioactive"
- define "bioactive renal cells" (BRC)
- define "selected renal cells" (SRC)
- define "native organ" and "native kidney"
- define "regenerative effect"
- define "admixture"
- explain "enriched" cell populations
- define "hypoxic" and "oxygen-tunable" culture conditions
- define "biomaterial"
- define "kidney disease"
- define "treatment" and "in vivo contacting"
- define various other terms (construct, formulation, Neo-Kidney Augment, Advance Cell Therapy, subject, patient, sample, test sample, control
- define regenerated kidney
- define hydrogel
- define adverse event
- define serious adverse event
- describe cell populations
- describe BRCs
- describe SRC
- describe therapeutic compositions
- describe bioactive selected renal cell populations
- describe source of cells
- describe cell populations derived from kidney biopsy
- describe cell populations derived from whole kidney tissue
- describe cell populations derived from in vitro cultures
- describe SRC obtained from isolation and expansion of renal cells
- describe characteristics of SRC
- describe biomaterials
- describe polymeric matrices
- describe hydrogels
- describe gelatin-based hydrogels
- describe bioactive cell formulations
- describe Neo-Kidney Augment (NKA)
- define biomaterials
- describe association of bioactive cell population with biomaterial
- motivate temperature-sensitive biomaterial
- summarize benefits of suspended cell population
- describe manufacturing process for bioactive cell formulations
- motivate cryopreservation of renal cells
- describe composition of bioactive cell formulation
- specify concentration of cells and gelatin in solution
- describe presentation of NKA in a sterile syringe
- calculate final volume of formulation
- describe therapeutically effective amount of bioactive renal cell populations
- summarize pharmaceutical compositions
- describe methods of use for constructs and formulations
- motivate administration of bioactive cells for treatment of disease
- describe indicators of kidney function
- motivate effective treatment of kidney disease
- describe methods of assessing regenerative outcome
- define administration methods
- describe modes of administration
- introduce surgical means of administration
- describe laparoscopic or percutaneous technique
- motivate injection into renal cortex
- describe distribution of therapeutic formulation
- introduce chronic kidney disease
- describe progressive staging of CKD
- define CKD stages according to GFR measurements
- describe standard-of-care in CKD
- introduce therapeutic product Neo Kidney Augment
- describe biologically active component SRC
- motivate therapeutic intervention with NKA
- describe treatment regimen
- determine therapeutic dose selection
- describe presentation of NKA
- determine number of treatments
- describe administration of BRC or SRC
- provide examples of administration

## EXAMPLES

### Example 1—PHASE I, Open-Label Safety and Delivery Optimization Study of an Autologous Neo-Kidney Augment (NKA) in Patients with Chronic Kidney Disease (TNG-CL010)

- introduce clinical trial
- describe patient selection
- outline treatment protocol
- detail preparation of Neo-Kidney Augment (NKA)
- describe implantation procedure
- outline MR imaging protocol
- describe renal scintigraphy protocol
- outline biochemical and other analyses
- present results of estimated glomerular filtration rate (eGFR)
- present results of serum creatinine (sCr)
- discuss implications of results
- summarize study findings

### Example 2—PHASE II, Open-Label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients with Type 2 Diabetes and Chronic Kidney Disease (RMCL-001)

- introduce therapeutic product
- describe NKA manufacturing process
- state study objectives
- define primary safety outcome measures
- define primary efficacy outcome measures
- state secondary objective
- define secondary safety and tolerability outcome measures
- state exploratory objective
- define exploratory outcome measures
- describe study design
- state randomization method
- describe control group
- state sample size
- describe study population
- list inclusion criteria
- list exclusion criteria
- describe study duration
- describe study enrollment
- outline investigational plan
- describe NKA dose
- outline safety monitoring
- introduce study design
- outline urine chemistry assessments
- describe research analytes
- outline pregnancy testing
- describe renal imaging procedures
- outline ultrasound procedures
- describe MRI procedures
- outline renal scintigraphy procedures
- describe surgical biopsy procedures
- outline guidance on wound care and pain management
- describe injection procedures
- outline percutaneous procedure
- describe laparoscopic procedure
- outline post-procedure evaluation
- present initial results of phase II study
- describe clinical outcomes
- present representative metabolic measures
- summarize efficacy of NKA injections

### Example 3—NKA Injection for Interventional Radiology

- outline clinic evaluation
- describe NKA delivery procedure
- detail needle placement and advancement
- outline NKA cell injection process
- specify post-injection evaluation

### Example 4—A Phase II, Open-Label Safety and Tolerability Study of an Autologous Neo-Kidney Augment (NKA) in Patients with Type 2 Diabetes and Chronic Kidney Disease (RMCL-002 and RMCL-003)

- introduce NKA product
- state study purpose
- define study objectives
- describe primary outcome measures
- describe secondary outcome measures
- outline exploratory objectives
- describe study design
- outline inclusion criteria
- outline exclusion criteria
- state number of sites
- introduce study design
- describe study duration
- outline study enrollment
- detail investigational plan
- describe renal biopsy procedure
- outline NKA injection procedure
- detail follow-up evaluations
- describe safety monitoring
- detail investigational product
- outline dosage and mode of administration
- describe statistical analysis methods
- provide rationale for two NKA injections
- discuss safety of two NKA injections
- outline laboratory assessments
- describe eGFR calculation
- detail routine urinalysis
- outline hematology assessments
- describe virus serology testing
- outline drug screen
- describe pregnancy screen
- detail renal imaging assessments

